MedTech Innovator, the world’s largest accelerator of medical technology companies, has announced that 24 medtech companies will participate in the fourth annual Asia Pacific Accelerator programme. The 2023 cohort companies will also compete for up to $300,000 in cash prizes and awards.

Over 400 companies applied for the Asia Pacific programme this year, and after a rigorous selection process, 60 companies were invited to pitch, 24 of which were named to the 2023 cohort. In early December, four startups from the 2023 Asia Pacific cohort will advance to compete in the Grand Finals to be held at APACMed’s Medtech Forum 2023 in Singapore.

The winning company, which will be determined by audience vote, stands to win a non-dilutive cash prize and the title of the 2023 MedTech Innovator Asia Pacific Winner.

The 20 startups picked for the annual accelerator programme include 3 from India (Accuster Technologies, Module Innovations, Weinnovate Biosolutions); 2 from US (Flexperc Medical, Astron Medtech); 5 from Singapore (Vivo Surgical, Thrixen, NICE Surgical Solutions, Neurowyzr, Kinexcs); 5 from China (Ossfila Technology, PrimaNova Technologies, Lifespans, Jdot (Changzhou) Medical Technology, GenLight Medical); 3 from South Korea (MedySapiens, Medipixel, Gbrain); 1 from Australia (Biotome) and 1 from Israel (Healium Medical). 

For the first time, MedTech Innovator Asia Pacific’s 2023 cohort will include four shortlisted companies that are part of the inaugural Olympus Asia Pacific Innovation Programme (OAIP)- BioCliq (India); NDR Medical (Singapore); Sonire Therapeutics (Japan); and Vesica Corporation (US).

The winning innovator will receive grant funding of $75,000 as well as an exclusive mentorship programme with key thought leaders from within Olympus.